Patient demographics and baseline disease characteristics
| . | High risk . | Standard risk . | Unknown* . | |||
|---|---|---|---|---|---|---|
| KRd (n = 48) . | Rd (n = 52) . | KRd (n = 147) . | Rd (n = 170) . | KRd (n = 201) . | Rd (n = 174) . | |
| Age, median y (range) | 60.5 (44.0-79.0) | 60.5 (41.0-84.0) | 65.0 (38.0-87.0) | 67.0 (36.0-84.0) | 63.0 (40.0-87.0) | 64.0 (31.0-91.0) |
| 18 to 64 y, n (%) | 33 (68.8) | 32 (61.5) | 66 (44.9) | 67 (39.4) | 112 (55.7) | 89 (51.1) |
| 65 to 74 y, n (%) | 11 (22.9) | 17 (32.7) | 63 (42.9) | 75 (44.1) | 68 (33.8) | 63 (36.2) |
| ≥75 y, n (%) | 4 (8.3) | 3 (5.8) | 18 (12.2) | 28 (16.5) | 21 (10.4) | 22 (12.6) |
| ECOG PS, n (%) | ||||||
| 0 | 18 (37.5) | 34 (65.4) | 66 (44.9) | 79 (46.5) | 81 (40.3) | 62 (35.6) |
| 1 | 23 (47.9) | 15 (28.8) | 68 (46.3) | 78 (45.9) | 100 (49.8) | 93 (53.4) |
| 2 | 7 (14.6) | 3 (5.8) | 13 (8.8) | 13 (7.6) | 20 (10.0) | 19 (10.9) |
| FISH, n (%) | ||||||
| t(4;14) | 33 (68.8) | 31 (59.6) | 0 | 0 | — | — |
| t(14;16) | 2 (4.2) | 8 (15.4) | 0 | 0 | — | — |
| del(17p) | ||||||
| ≥60% of plasma cells | 17 (35.4) | 20 (38.5) | 0 | 0 | — | — |
| <60% of plasma cells | 1 (2.1) | 1 (1.9) | 3 (2.0) | 7 (4.1) | — | — |
| Creatinine clearance − mean mL/min ± SD | 85.3 ± 23.9 | 91.7 ± 29.1 | 84.2 ± 28.1 | 83.3 ± 28.5 | 85.4 ± 30.7 | 86.7 ± 32.1 |
| <50 mL/min, n (%) | 2 (4.2) | 2 (3.8) | 9 (6.1) | 17 (10.0) | 14 (7.0) | 13 (7.5) |
| ≥50 mL/min, n (%) | 46 (95.8) | 49 (94.2) | 138 (93.9) | 152 (89.4) | 186 (92.5) | 157 (90.2) |
| Missing, n (%) | 0 | 1 (1.9) | 0 | 1 (0.6) | 1 (0.5) | 4 (2.3) |
| Serum β2-microglobulin level, n (%) | ||||||
| <2.5 mg/L | 9 (18.8) | 8 (15.4) | 25 (17.0) | 35 (20.6) | 43 (21.4) | 34 (19.5) |
| ≥2.5 mg/L | 39 (81.3) | 44 (84.6) | 122 (83.0) | 135 (79.4) | 158 (78.6) | 140 (80.5) |
| Number of prior lines of therapy, median (range) | 2.0 (1-4) | 2.0 (1-3) | 2.0 (1-3) | 2.0 (1-4) | 2.0 (1-3) | 2.0 (1-3) |
| Prior therapy, n (%) | ||||||
| Bortezomib | 39 (81.3) | 35 (67.3) | 90 (61.2) | 105 (61.8) | 132 (65.7) | 120 (69.0) |
| Lenalidomide | 13 (27.1) | 12 (23.1) | 28 (19.0) | 35 (20.6) | 38 (18.9) | 31 (17.8) |
| . | High risk . | Standard risk . | Unknown* . | |||
|---|---|---|---|---|---|---|
| KRd (n = 48) . | Rd (n = 52) . | KRd (n = 147) . | Rd (n = 170) . | KRd (n = 201) . | Rd (n = 174) . | |
| Age, median y (range) | 60.5 (44.0-79.0) | 60.5 (41.0-84.0) | 65.0 (38.0-87.0) | 67.0 (36.0-84.0) | 63.0 (40.0-87.0) | 64.0 (31.0-91.0) |
| 18 to 64 y, n (%) | 33 (68.8) | 32 (61.5) | 66 (44.9) | 67 (39.4) | 112 (55.7) | 89 (51.1) |
| 65 to 74 y, n (%) | 11 (22.9) | 17 (32.7) | 63 (42.9) | 75 (44.1) | 68 (33.8) | 63 (36.2) |
| ≥75 y, n (%) | 4 (8.3) | 3 (5.8) | 18 (12.2) | 28 (16.5) | 21 (10.4) | 22 (12.6) |
| ECOG PS, n (%) | ||||||
| 0 | 18 (37.5) | 34 (65.4) | 66 (44.9) | 79 (46.5) | 81 (40.3) | 62 (35.6) |
| 1 | 23 (47.9) | 15 (28.8) | 68 (46.3) | 78 (45.9) | 100 (49.8) | 93 (53.4) |
| 2 | 7 (14.6) | 3 (5.8) | 13 (8.8) | 13 (7.6) | 20 (10.0) | 19 (10.9) |
| FISH, n (%) | ||||||
| t(4;14) | 33 (68.8) | 31 (59.6) | 0 | 0 | — | — |
| t(14;16) | 2 (4.2) | 8 (15.4) | 0 | 0 | — | — |
| del(17p) | ||||||
| ≥60% of plasma cells | 17 (35.4) | 20 (38.5) | 0 | 0 | — | — |
| <60% of plasma cells | 1 (2.1) | 1 (1.9) | 3 (2.0) | 7 (4.1) | — | — |
| Creatinine clearance − mean mL/min ± SD | 85.3 ± 23.9 | 91.7 ± 29.1 | 84.2 ± 28.1 | 83.3 ± 28.5 | 85.4 ± 30.7 | 86.7 ± 32.1 |
| <50 mL/min, n (%) | 2 (4.2) | 2 (3.8) | 9 (6.1) | 17 (10.0) | 14 (7.0) | 13 (7.5) |
| ≥50 mL/min, n (%) | 46 (95.8) | 49 (94.2) | 138 (93.9) | 152 (89.4) | 186 (92.5) | 157 (90.2) |
| Missing, n (%) | 0 | 1 (1.9) | 0 | 1 (0.6) | 1 (0.5) | 4 (2.3) |
| Serum β2-microglobulin level, n (%) | ||||||
| <2.5 mg/L | 9 (18.8) | 8 (15.4) | 25 (17.0) | 35 (20.6) | 43 (21.4) | 34 (19.5) |
| ≥2.5 mg/L | 39 (81.3) | 44 (84.6) | 122 (83.0) | 135 (79.4) | 158 (78.6) | 140 (80.5) |
| Number of prior lines of therapy, median (range) | 2.0 (1-4) | 2.0 (1-3) | 2.0 (1-3) | 2.0 (1-4) | 2.0 (1-3) | 2.0 (1-3) |
| Prior therapy, n (%) | ||||||
| Bortezomib | 39 (81.3) | 35 (67.3) | 90 (61.2) | 105 (61.8) | 132 (65.7) | 120 (69.0) |
| Lenalidomide | 13 (27.1) | 12 (23.1) | 28 (19.0) | 35 (20.6) | 38 (18.9) | 31 (17.8) |
ECOG PS, Eastern Cooperative Oncology Group performance status; SD, standard deviation.
The unknown risk subgroup included patients who had FISH assessment, but the results of 1 or more genetic subtypes were not available.